An update on current and prospective immunotherapies for chronic lymphocytic leukemia

被引：0

作者：

Emole, Josephine N. ^{[1
]}

Locke, Frederick L. ^{[2
]}

Pinilla-Ibarz, Javier ^{[1
]}

机构：

[1] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL 33612 USA

[2] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Dept Blood & Marrow Transplantat, Tampa, FL 33612 USA

来源：

IMMUNOTHERAPY | 2015年 / 7卷 / 04期

关键词：

bispecific T-cell engager; chimeric antigen receptor; chronic lymphocytic leukemia; immunotherapy; monoclonal antibody; STEM-CELL TRANSPLANTATION; PREVIOUSLY UNTREATED PATIENTS; FLUDARABINE PLUS CYCLOPHOSPHAMIDE; TUMOR-ASSOCIATED ANTIGENS; PHASE-II TRIAL; TERM-FOLLOW-UP; T-CELLS; INITIAL THERAPY; CD20; ANTIGEN; OPEN-LABEL;

D O I：

10.2217/IMT.15.14

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Chronic lymphocytic leukemia (CLL) is the most common leukemia. Combined agent chemotherapy is the current standard front-line treatment for physically fit patients with CLL. Use of chemotherapy can be complicated by significant toxicity, especially in patients with advanced age or comorbid conditions. Moreover, patients may relapse and become refractory to further chemotherapy. Immunotherapy targets the aberrant immunological processes in CLL without the toxicity of chemotherapy. Immunotherapeutic strategies can also be combined with chemotherapy to improve response rates in this incurable disease. In this review, we evaluate current and future immune-based options in the treatment of CLL.

引用

页码：455 / 466

页数：12

共 50 条

[1] Current results and prospective trials of cladribine in chronic lymphocytic leukemia
Tallman, MS
Hakimian, D
[J]. SEMINARS IN HEMATOLOGY, 1996, 33 (01) : 23 - 27
[2] Update on Therapy of Chronic Lymphocytic Leukemia
Gribben, John G.
O'Brien, Susan
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (05) : 544 - 550
[3] Update in the management of chronic lymphocytic leukemia
Kami J Maddocks
Thomas S Lin
[J]. Journal of Hematology & Oncology, 2
[4] Update in the management of chronic lymphocytic leukemia
Maddocks, Kami J.
Lin, Thomas S.
[J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2009, 2
[5] Update on the biology of chronic lymphocytic leukemia
Bannerji, R
Byrd, JC
[J]. CURRENT OPINION IN ONCOLOGY, 2000, 12 (01) : 22 - 29
[6] Update on Signal Inhibitors in Chronic Lymphocytic Leukemia
Boddu, Prajwal
Jain, Nitin
[J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (04) : 279 - 288
[7] Chronic Lymphocytic Leukemia: An Update on Biology and Treatment
John C. Riches
Alan G. Ramsay
John G. Gribben
[J]. Current Oncology Reports, 2011, 13 : 379 - 385
[8] Chronic lymphocytic leukemia: ASH update 2014
Steurer M.
[J]. memo - Magazine of European Medical Oncology, 2015, 8 (3) : 159 - 161
[9] Chronic Lymphocytic Leukemia: An Update on Biology and Treatment
Riches, John C.
Ramsay, Alan G.
Gribben, John G.
[J]. CURRENT ONCOLOGY REPORTS, 2011, 13 (05) : 379 - 385
[10] An update on the efficacy of Venetoclax for chronic lymphocytic leukemia
Lovell, Alexandra R.
Sawyers, Jacki
Bose, Prithviraj
[J]. EXPERT OPINION ON PHARMACOTHERAPY, 2023, 24 (11) : 1307 - 1316

← 1 2 3 4 5 →